In the article, C&EN assistant editor Carmen Drahl describes potential new migraine medications that may be safer and more effective than existing drugs. A class of compounds called triptans, which target dilation of brain arteries, now are the mainstays for fighting migraines. Although effective, they tend to work slowly and carry risks for individuals with underlying heart disease.
Several pharmaceutical companies are working on new treatments for migraine that target signaling proteins in the brain, including a receptor for a neuropeptide and a type of ion channel. In laboratory studies, these approaches appear to reduce the risk of side effects, the article notes.
One exciting approach currently in clinical trials involves using a cell-phone sized device that is triggered by the airflow from inhaling. The inhaler delivers a migraine drug in a user-friendly way and is faster-acting than conventional treatments, Drahl writes.
ARTICLE #5 EMBARGOED FOR 9 A.M., EASTERN TIME, Oct. 1, 2007 New tactics for trouncing migraine
This story will be available on Oct. 1 at: http://pubs.acs.org/cen/science/85/8540sci2.html
FOR ADVANCE INFORMATION, CONTACT:
ACS News Service
FOR WIRED READERS
Science Elements: An ACS Podcast www.chemistry.org/science_elements.html
The ACS Office of Communications is podcasting PressPac contents in order to make cutting-edge scientific discoveries from ACS journals available to a broad public audience at no charge. Science Elements includes selected content from A
|Contact: Michael Woods|
American Chemical Society